Literature DB >> 31400350

Nanocarrier-based systems for targeted and site specific therapeutic delivery.

Joydeb Majumder1, Oleh Taratula2, Tamara Minko3.   

Abstract

Systemic drug delivery methods such as oral or parenteral administration of free drugs possess relatively low treatment efficiency and marked adverse side effects. The use of nanoparticles for drug delivery in most cases substantially enhances drug efficacy, improves pharmacokinetics and drug release and limits their side effects. However, further enhancement in drug efficacy and significant limitation of adverse side effects can be achieved by specific targeting of nanocarrier-based delivery systems especially in combination with local administration. The present review describes major advantages and limitations of organic and inorganic nanocarriers or living cell-based drug and nucleic acid delivery systems. Among these, different nanoparticles, supramolecular gels, therapeutic cells as living drug carriers etc. have emerged as a new frontier in modern medicine.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell-based carriers; Drug; Drug targeting; Organic and inorganic nanoparticles; Supramolecular gel; siRNA and nucleotide delivery

Mesh:

Year:  2019        PMID: 31400350      PMCID: PMC6748653          DOI: 10.1016/j.addr.2019.07.010

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  29 in total

Review 1.  Membrane-core nanoparticles for cancer nanomedicine.

Authors:  Jianfeng Guo; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-22       Impact factor: 15.470

Review 2.  Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.

Authors:  Abraham S Moses; Ananiya A Demessie; Olena Taratula; Tetiana Korzun; Ov D Slayden; Oleh Taratula
Journal:  Small       Date:  2021-01-25       Impact factor: 13.281

Review 3.  Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer.

Authors:  Rajeswari Raguraman; Akhil Srivastava; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-08-08       Impact factor: 15.470

Review 4.  Multifunctional Role of Silica in Pharmaceutical Formulations.

Authors:  Yating Gao; Yue Zhang; Yanlong Hong; Fei Wu; Lan Shen; Youjie Wang; Xiao Lin
Journal:  AAPS PharmSciTech       Date:  2022-03-16       Impact factor: 3.246

5.  Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells.

Authors:  Andrei A Kramerov; Ruchi Shah; Hui Ding; Eggehard Holler; Sue Turjman; Yaron S Rabinowitz; Sean Ghiam; Ezra Maguen; Clive N Svendsen; Mehrnoosh Saghizadeh; Julia Y Ljubimova; Alexander V Ljubimov
Journal:  Nanomedicine       Date:  2020-11-10       Impact factor: 5.307

Review 6.  Recent progress in nanomedicine for enhanced cancer chemotherapy.

Authors:  Guoqing Wei; Yu Wang; Guang Yang; Yi Wang; Rong Ju
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

7.  Intelligent phototriggered nanoparticles induce a domino effect for multimodal tumor therapy.

Authors:  Xiao Xu; Chao Han; Can Zhang; Dan Yan; Chunling Ren; Lingyi Kong
Journal:  Theranostics       Date:  2021-04-19       Impact factor: 11.556

8.  CXCL5 Modified Nanoparticle Surface Improves CXCR2+ Cell Selective Internalization.

Authors:  Roberta Cagliani; Francesca Gatto; Giulia Cibecchini; Roberto Marotta; Federico Catalano; Paola Sanchez-Moreno; Pier Paolo Pompa; Giuseppe Bardi
Journal:  Cells       Date:  2019-12-24       Impact factor: 6.600

Review 9.  Unveiling ncRNA regulatory axes in atherosclerosis progression.

Authors:  Estanislao Navarro; Adrian Mallén; Josep M Cruzado; Joan Torras; Miguel Hueso
Journal:  Clin Transl Med       Date:  2020-02-03

10.  M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma.

Authors:  Xueliang Zuo; Zhiqiang Chen; Wen Gao; Yao Zhang; Jinguo Wang; Junfeng Wang; Ming Cao; Juan Cai; Jindao Wu; Xuehao Wang
Journal:  J Hematol Oncol       Date:  2020-01-08       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.